Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Guo, Xiaojinga | Liu, Yujiea | Huang, Xiaa | Wang, Yunb; c | Qu, Jinb; c | Lv, Yingpina; *
Affiliations: [a] Department of Reproductive Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China | [b] Department of Gynaecology, People’s Hospital of Jining, Jining, Shandong, China | [c] Department of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Correspondence: [*] Corresponding author: Yingpin Lv, Department of Reproductive Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. E-mail: [email protected].
Abstract: BACKGROUND AND AIM: Relaxin is a short circulating peptide hormone. The aim of this study was to understand the role of relaxin in progression of epithelial ovarian cancer (EOC) and to assess its diagnostic and prognostic significance. METHODS: A total of 124 patients with EOC, 46 patients with benign ovarian diseases, and 50 healthy controls were recruited. Serum levels of relaxin were determined by ELISA method. The relationship between serum relaxin level and each of the clinicopathological parameters was analyzed using the χ2 test. Survival curves were plotted using the Kaplan-Meier method. The statistical difference in survival between the different groups was compared using the log-rank test. Survival correlation with the prognostic factors was further investigated by multivariate analysis using the Cox proportional hazards model with backward stepwise likelihood ratio. RESULTS: The results showed that serum relaxin level was significantly higher in patients with EOC than those with benign ovarian diseases and healthy controls (p< 0.01). Serum relaxin level was associated with FIGO stage, lymph node metastasis, tumor resectability, survival of the patients, chemotherapy and tumor recurrence (p< 0.05). Analysis using the Kaplan-meier method indicated that patients with high serum relaxin had significantly shorter overall survival time than those with low relaxin (p< 0.01). In a multivariate analysis along with clinical prognostic parameters, serum relaxin was identified as an independent adverse prognostic variable for survival. CONCLUSIONS: These results indicated that serum relaxin may be a clinically useful indicator for diagnostic and prognostic evaluation in EOC patients.
Keywords: Epithelial ovarian cancer, metastasis, prognosis, marker, relaxin
DOI: 10.3233/CBM-170278
Journal: Cancer Biomarkers, vol. 21, no. 1, pp. 81-87, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]